Related Experiment Video
Updated: Jul 3, 2026
17:50
Preventing the Spread of Malaria and Dengue Fever Using Genetically Modified Mosquitoes
Published on: July 4, 2007
Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants
Armin Spök1, Richard M Twyman, Rainer Fischer
1Inter-University Research Centre for Technology, Work and Culture (IFZ), Schlögelgasse 2, A-8010 Graz, Austria.
Trends in Biotechnology
|August 5, 2008
Summary
Genetically modified plants for pharmaceuticals face evolving regulations. Harmonizing international rules for plant-made pharmaceuticals is crucial for industry growth and reducing uncertainty.
Area of Science:
- Biotechnology
- Pharmaceutical Regulation
- Plant Science
Background:
- Genetically modified (GM) plants are increasingly used to produce pharmaceutical proteins.
- This dual application intersects the regulatory frameworks for GM crops and biopharmaceuticals.
- Plant-made pharmaceuticals (PMPs), also known as plant-derived pharmaceuticals (PDPs), have unique regulatory challenges.
Purpose of the Study:
- To review the current global regulatory landscape for PMPs.
- To discuss recent regulatory changes and identify areas needing further development.
- To advocate for international harmonization of PMP regulations.
Main Methods:
- Review of existing regulations and guidelines across different countries.
- Analysis of recent developments in PMP regulatory frameworks.
- Discussion of the impact of emerging PMP products on regulatory evolution.
Main Results:
- Regulatory frameworks for PMPs are still developing and vary internationally.
- Products nearing commercialization are testing and refining these evolving regulations.
- There is a clear need for more comprehensive and harmonized international regulations.
Conclusions:
- The burgeoning PMP industry requires updated and harmonized regulatory approaches.
- Fine-tuning regulations through near-commercial products can reduce industry uncertainty.
- International collaboration is essential for the successful and safe development of plant-made pharmaceuticals.
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
02:50Transgenic Plants
Recombinant DNA technology called transgenesis is often used to add a foreign gene or remove a detrimental gene from an organism. Such genetically modified organisms are called transgenic organisms.
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
00:49What is Genetic Engineering?
Overview
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).